| Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. | |
| | |
MedLine Citation:
|
PMID: 12817430 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Although some studies have examined the expression of aberrant markers such as CD2, CD7, CD10, CD13, CD33, and CD34 on B cells in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), a uniform multiparametric analysis of the frequency of expression of these markers using stringent criteria is lacking. By using 3-color flow cytometry, we analyzed 117 cases (bone marrow, 71; blood, 31; lymph nodes, 15) for coexpression of aberrant markers with CD19. Marker expression was considered positive when present on at least 20% of CD19+ cells. Of 117 cases, 40 (34.2%) showed expression of 1 or more aberrant markers. Expression of 4 aberrant markers was seen in 1 case, 3 in 4 cases, 2 in 15 cases, and 1 in 20 cases. Kaplan-Meier survival curves and the log-rank test revealed that the group with aberrant markers showed significantly shortened overall survival compared with the group without aberrant markers (P < .001). There is considerable phenotypic heterogeneity in CLL/SLL, and expression of aberrant markers indicates aggressiveness. |
| | |
Authors:
|
Bal Kampalath; Maurice P Barcos; Carleton Stewart |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of clinical pathology Volume: 119 ISSN: 0002-9173 ISO Abbreviation: Am. J. Clin. Pathol. Publication Date: 2003 Jun |
Date Detail:
|
Created Date: 2003-06-23 Completed Date: 2003-07-02 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370470 Medline TA: Am J Clin Pathol Country: United States |
Other Details:
|
Languages: eng Pagination: 824-32 Citation Subset: AIM; IM |
Affiliation:
|
Dept of Pathology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antibodies, Monoclonal Antigens, CD / analysis Antigens, CD13 / analysis Antigens, CD19 / analysis Antigens, CD2 / analysis Antigens, CD34 / analysis Antigens, CD7 / analysis Antigens, Differentiation, Myelomonocytic / analysis B-Lymphocytes / immunology* Bone Marrow / immunology Female Flow Cytometry Humans Immunophenotyping* Leukemia, Lymphocytic, Chronic, B-Cell / immunology*, mortality Lymph Nodes / immunology Male Middle Aged Neprilysin / analysis Survival Rate |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antigens, CD; 0/Antigens, CD19; 0/Antigens, CD2; 0/Antigens, CD34; 0/Antigens, CD7; 0/Antigens, Differentiation, Myelomonocytic; 0/CD33 antigen; EC 3.4.11.2/Antigens, CD13; EC 3.4.24.11/Neprilysin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Rhabdomyomatous multilocular thymic cyst.
Next Document: Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathol...